Page Image

Heme Today

Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.

Myelofibrosis Trial: Combining a BET and JAK Inhibitor Might Be Better Than SOC

MANIFEST-2 compares pelabresib plus ruxolitinib with placebo plus ruxolitinib for JAK-inhibitor-naive disease.

Advertisement

Latest News

Advertisement

Conference Coverage

Blood Cancer Awareness

Advertisement
Advertisement